Abstract
Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria. This was a retrospective, observational cohort study, using pharmacovigilance data systematically collected at all MDR-TB treatment centers in Nigeria. Characteristics of AEs during the intensive phase treatment were documented, and risk factors for development of AEs were assessed. Four hundred and sixty patients were included in the analysis: 62% were male; median age was 33 years [Interquartile Range (IQR):28-42] and median weight was 51 kg (IQR: 45-59). Two hundred and three (44%) patients experienced AEs; four died of conditions associated with SLD AEs. Gastro-intestinal (n = 100), neurological (n = 75), ototoxic (n = 72) and psychiatric (n = 60) AEs were the most commonly reported, whereas ototoxic and psychiatric AEs were the most debilitating. Majority of AEs developed after 1-2 months of therapy, and resolved in less than a month after treatment. Some treatment centers were twice as likely to report A...Continue Reading
References
Jan 1, 1986·British Journal of Clinical Pharmacology·J P Griffin
Mar 28, 1998·British Journal of Clinical Pharmacology·N MooreM Mabille
Apr 29, 1998·JAMA : the Journal of the American Medical Association·J LazarouP N Corey
Oct 28, 1999·PharmacoEconomics·T J WhiteJ P Rho
Jun 20, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Robert C NelsonVictor Gogolak
Jan 25, 2005·Lancet·Vaira LeimaneCharles D Wells
Jan 10, 2008·The Journal of Infectious Diseases·Jason R AndrewsUNKNOWN Tugela Ferry Care and Research (TF CARES) Collaboration
Mar 28, 2008·Bulletin of the World Health Organization·Niyi Awofeso
Jan 10, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Elena Lopez-GonzalezAdolfo Figueiras
Dec 17, 2009·Pharmacoepidemiology and Drug Safety·J O Ohaju-Obodo, O I Iribhogbe
May 25, 2010·BMC Public Health·Yin Yin XiaSi Yan Zhan
Sep 17, 2010·Pharmacoepidemiology and Drug Safety·I A OreagbaS O Olayemi
Jun 28, 2011·Pharmacoepidemiology and Drug Safety·Abiodun Adefurin
May 16, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M W CarrollC E Barry
Jun 8, 2012·The New England Journal of Medicine·Maria Tarcela GlerCharles D Wells
Jul 14, 2012·PloS One·Petros IsaakidisTony Reid
Jul 26, 2012·Lancet·Andreas H DiaconMelvin K Spigelman
Jan 18, 2013·PloS One·Miranda W LangendamAndreas Sandgren
May 15, 2013·PloS One·Karen SheanKeertan Dheda
Aug 7, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Evans SagwaAukje K Mantel-Teeuwisse
Dec 7, 2013·The International Journal of Risk & Safety in Medicine·Adeline OsakweIretiola Fajolu
Apr 12, 2014·PloS One·Olanrewaju OladimejiLuis E Cuevas
Aug 2, 2014·Tuberculosis·Zikun HuangJunming Li
Citations
Oct 23, 2015·Tropical Medicine & International Health : TM & IH·Joseph S CavanaughJames D Heffelfinger
Jul 29, 2016·PloS One·Nafees AhmadAmer Hayat Khan
Mar 9, 2017·BMC Health Services Research·Daniel WirthRobert Hettle
Jan 23, 2018·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
Aug 23, 2018·PloS One·Yohanna Kambai AvongOlumide A T Ogundahunsi
Mar 5, 2016·American Journal of Therapeutics·Nafees AhmadAmer Hayat Khan
Aug 7, 2018·Global Health Action·Jaya Prasad TripathyAnthony D Harries
Mar 1, 2019·PloS One·Gina GualanoFabrizio Palmieri
Jun 18, 2019·Infectious Diseases of Poverty·Daniel Chukwuemeka Ogbuabor, Obinna Emmanuel Onwujekwe
Mar 29, 2019·BMC Infectious Diseases·Mehari Woldemariam MeridMelaku Kindie Yenit
Aug 20, 2019·Health and Quality of Life Outcomes·Ammar Ali Saleh Jaber, Baharudin Ibrahim
Oct 13, 2019·European Respiratory Review : an Official Journal of the European Respiratory Society·Edine TiemersmaMichael Kimerling
Jun 5, 2020·BMC Public Health·R HuqueJ Newell
Dec 4, 2020·BMC Infectious Diseases·Arjunkumar JakasaniaSoundappan Kathirvel
Mar 5, 2021·PloS One·Gilbert LazarusVivian Soetikno
Oct 10, 2021·BMC Health Services Research·Everdina W TiemersmaLinda Härmark